Ukr.Biochem.J. 2016; Том 88, № 2, березень-квітень, c. 35-44

doi: http://dx.doi.org/10.15407/ubj88.02.035

Серцево-судинні захворювання у хворих на цукровий діабет 2-го типу: гомоцистеїн як маркер запалення

27.04.2016   Без категорії   No comments

Ashok Sahu1, Trapti Gupta2, Arvind Kavishwar3, R. K. Singh4

1MGM Medical College Indore, Jabalpur, India;
e-mail: asahu888@gmail.com; asahu888@yahoo.co.in;
2NSCB Medical College, Jabalpur, India;
3Regional Malaria Research Centre of Tribal (ICMR), Jabalpur, India;
4Chirayu Hospital, Bhopal, India

Вважається, що запалення відіграють певну роль у патогенезі серцево-судинних захворювань; вимірювання маркерів запалення дозволяє покращити оцінку ризику серцево-судинних захворювань (ССЗ). Гіпергомоцистеїнемія корелює з виникненням тромбів, інфарктів й інсультів, хоча неясно, чи є гіпергомоцистеїнемія незалежним чинником ризику для цих умов. У роботі досліджували роль гомоцистеїну у хворих на діабет із ССЗ в Індії, штат Мадх’я-Прадеш. Досліджували дві групи хворих на діабет (типу 2): група І (n = 50) – без ССЗ і група ІІ (n = 50) наявність ССЗ доведена методом ангіографії. У сироватці крові вимірювали С-реактивний протеїн (YS-CRP), фібриноген і ліпопротеїн (а). Також вимірювали вміст гомоцистеїну, глюкози в плазмі, швидкість зсідання еритроцитів та концентрацію глікозильованого гемоглобіну. Рівень екскреції альбуміну і кліренс креатиніну вимірювали в сечі для оцінки роботи нирок. Показано, що рівні гомоцистеїну та інших маркерів запалення були значно підвищені в групі II (n = 50) в порівнянні з групою I. Спостерігали кореляцію між гіпергомоцистеїнемією та маркерами запалення в пацієнтів із порушеною функцією нирок. Дійшли висновку про те, що порушення функції нирок є ключовим фактором, який впливає на рівень гомоцистеїну.

Ключові слова: , , , , , ,

Посилання:

  1. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001 May 16;285(19):2481-5. PubMed, CrossRef
  2. Elkind MS, Cheng J, Boden-Albala B, Rundek T, Thomas J, Chen H, Rabbani LE, Sacco RL. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke. 2002 Jan;33(1):31-7. PubMed, PubMedCentral, CrossRef
  3. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998 Jan 15;128(2):127-37. Review. PubMed, CrossRef
  4. Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey WT; DCCT/ECIC STUDY GROUP. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care. 2003 May;26(5):1439-48. PubMed, CrossRef
  5. Torbus-Lisiecka B, Bukowska H, Jastrzebska M, Chelstowski K, Honczarenko K, Naruszewicz M. Lp(a), homocysteine and a family history of early ischemic cerebral stroke. Nutr Metab Cardiovasc Dis. 2001 Oct;11 Suppl 5:52-9. PubMed
  6. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002 Apr;51(4):1157-65. PubMed, CrossRef
  7. Ceriello A, Taboga C, Giacomello R, Falleti E, De Stasio G, Motz E, Lizzio S, Gonano F, Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes. 1994 Mar;43(3):430-2. PubMed, CrossRef
  8. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care. 2000 Dec;23(12):1816-22. PubMed, CrossRef
  9. Koning ABL, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003 Sep;36(6):431–441. CrossRef
  10. Abdella NA, Mojiminiyi OA, Akanji AO, Moussa MA. Associations of plasma homocysteine concentration in subjects with type 2 diabetes mellitus. Acta Diabetol. 2002 Dec;39(4):183-90. PubMed, CrossRef
  11. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999 Sep 14;100(11):1161-8. PubMed, CrossRef
  12. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001 Nov 20;104(21):2569-75. PubMed, CrossRef
  13. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2074-81. PubMed, CrossRef
  14. Al-Obaidi MK, Philippou H, Stubbs PJ, Adami A, Amersey R, Noble MM, Lane DA. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation. 2000 Feb 1;101(4):372-7. PubMed, CrossRef
  15. Voutilainen S, Morrow JD, Roberts LJ 2nd, Alfthan G, Alho H, Nyyssönen K, Salonen JT. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1263-6. PubMed, CrossRef
  16. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J, Turner RM, Thompson SG, Kooner JS. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet. 2000 Feb 12;355(9203):523-7. PubMed, CrossRef
  17. Nair KG, Nair SR, Ashavaid TF, Dalal JJ, Eghlim FF. Methylenetetrahydrofolate reductase gene mutation and hyperhomocysteinemia as a risk factor for coronary heart disease in the Indian population. J Assoc Physicians India. 2002 May;50 Suppl:9-15. PubMed
  18. Snehalatha C, Ramachandran A, Satyavani K, Sivasankari S, Sathyamurthy I, Viswanathan V. Plasma homocysteine concentration and coronary artery disease in Asian Indians. J Assoc Physicians India. 2002 Oct;50:1229-31. PubMed
  19. Deepa R, Velmurugan K, Saravanan G, Karkuzhali K, Dwarakanath V, Mohan V. Absence of association between serum homocysteine levels and coronary artery disease in south Indian males. Indian Heart J. 2001 Jan-Feb;53(1):44-7. PubMed
  20. Laessig RH, Indriksons AA, Hassemer DJ, Paskey TA, Schwartz TH. Changes in serum chemical values as a result of prolonged contact with the clot. Am J Clin Pathol. 1976 Sep;66(3):598-604. PubMed, CrossRef
  21. Tsuchiya M, Asada A, Kasahara E, Sato EF, Shindo M, Inoue M. Smoking a single cigarette rapidly reduces combined concentrations of nitrate and nitrite and concentrations of antioxidants in plasma. Circulation. 2002 Mar 12;105(10):1155-7. PubMed,  CrossRef
  22. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan 10;363(9403):157-63. Review. PubMed, CrossRef
  23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52. PubMed, CrossRef
  24. Definition, Diagnosis and classification of diabetes mellitus and its complications. World Health Organization 1999.
  25. National Cholesterol Education Program National Heart, Lung, and Blood Institute National Institutes of Health NIH Publication No. 02-5215 September 2002.
  26. Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, Tverdal A, Tell GS, Nygård O, Vollset SE. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006 Jun;136(6 Suppl):1731S-1740S. Review. PubMed
  27. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001 Apr 3;103(13):1813-8. PubMed, CrossRef
  28. Dati F, Tate JR, Marcovina SM, Steinmetz A. First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay – Lp(a) SRM 2B. Clin Chem Lab Med. 2004;42(6):670-6. PubMed, CrossRef
  29. Wetteland P, Røger M, Solberg HE, Iversen OH. Population-based erythrocyte sedimentation rates in 3910 subjectively healthy Norwegian adults. A statistical study based on men and women from the Oslo area. J Intern Med. 1996 Sep;240(3):125-31. PubMed, CrossRef
  30. Whitton CM, Sands D, Hubbard AR, Gaffney PJ. A collaborative study to establish the 2nd International Standard for Fibrinogen, Plasma. Thromb Haemost. 2000 Aug;84(2):258-62. PubMed
  31. Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood. 2000 Aug 1;96(3):966-72. PubMed
  32. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation. 2000 Apr 4;101(13):1506-11. PubMed, CrossRef
  33. Yu HH, Joubran R, Asmi M, Law T, Spencer A, Jouma M, Rifai N. Agreement among four homocysteine assays and results in patients with coronary atherosclerosis and controls. Clin Chem. 2000 Feb;46(2):258-64. PubMed
  34. Zylberstein DE, Bengtsson C, Björkelund C, Landaas S, Sundh V, Thelle D, Lissner L. Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation. 2004 Feb 10;109(5):601-6. PubMed,  CrossRef
  35. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol. 1998 Oct;9(5):441-8. Review. PubMed, CrossRef
  36. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1995 Apr 25;92(9):3893-7. PubMed, PubMedCentral, CrossRef
  37. Festa A, D’Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000 Oct;58(4):1703-10. PubMed, CrossRef
  38. Hommels MJ, van der Ven AJ, Kroon AA, Kessels AG, van Dieijen-Visser MP, van Engelshoven JA, Bruggeman CA, de Leeuw PW. C-reactive protein, atherosclerosis and kidney function in hypertensive patients. J Hum Hypertens. 2005 Jul;19(7):521-6. PubMed, CrossRef
  39. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999 Jan 5-12;99(1):178-82. PubMed, CrossRef
  40. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest. 1993 Apr;91(4):1351-7. PubMed, PubMedCentral, CrossRef
  41. de Winter RJ, Fischer J, Bholasingh R, van Straalen JP, de Jong T, Tijssen JG, Sanders GT. C-Reactive protein and cardiac troponin T in risk stratification: differences in optimal timing of tests early after the onset of chest pain. Clin Chem. 2000 Oct;46(10):1597-603. PubMed
  42. Vykoukal D, Davies MG.  Vascular biology of metabolic syndrome. J Vasc Surg. 2011 Sep;54(3):819-31. PubMed, PubMedCentral, CrossRef
  43. Catena C, Zingaro L, Casaccio D, Sechi LA. Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. Am J Med. 2000 Nov;109(7):556-61.
    PubMed, CrossRef
  44. Sechi LA, Zingaro L, Bartoli E. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med. 1999; 130(12):1028-1029. CrossRef
  45. Sechi LA, Zingaro L, Catena C, Perin A, De Marchi s, Baroli E. Lipoprotien (a) and apolipoprotien (a) isoforms and proteinuria in patients with moderate renal failure. Clin J Am Soc Nephrol. 1995; 6(3):402.
  46. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000 Sep 5;102(10):1082-5. PubMed, CrossRef
  47. Yilmaz N, Ciçek HK, Celik A, Meram I, Kocabas R, Davutoglu V. Diagnostic value of homocysteine, C-reactive protein and bilirubin for coronary artery disease. East Mediterr Health J. 2007 May-Jun;13(3):522-35. PubMed
  48. Aso Y, Yoshida N, Okumura K, Wakabayashi S, Matsutomo R, Takebayashi K, Inukai T. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta. 2004 Oct;348(1-2):139-45. PubMed, CrossRef
  49. Gori AM, Corsi AM, Fedi S, Gazzini A, Sofi F, Bartali B, Bandinelli S, Gensini GF, Abbate R, Ferrucci L. A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am J Clin Nutr. 2005 Aug;82(2):335-41. PubMed
  50. Jonasson T, Ohlin AK, Gottsäter A, Hultberg B, Ohlin H. Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease–a prospective randomized study of vitamin supplementation. Clin Chem Lab Med. 2005;43(6):628-34. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.